Street Calls of the Week
Adaptimmune Therapeutics PLC (NASDAQ:ADAP), currently trading near its 52-week low of $0.05 and down over 95% in the past year, reported that Chief Financial Officer Gavin Wood sold 96,000 ordinary shares of the company on September 2, 2025, for $0.0099 per share, representing a total transaction value of $950.
Following the transaction, Wood directly holds no ordinary shares in the form of American Depositary Shares (ADS). Each ADS represents six ordinary shares of the Issuer. However, Wood holds nominal cost options and other options covering an aggregate of 11,140,760 ordinary shares of Adaptimmune Therapeutics . The company currently faces significant challenges, with InvestingPro analysis showing weak financial health metrics and rapid cash burn. For detailed insights and 16 additional key ProTips about ADAP’s financial position, investors can access the comprehensive Pro Research Report on InvestingPro.
In other recent news, Adaptimmune Therapeutics Plc announced its second-quarter 2025 earnings, which revealed a surprising revenue beat. However, the company reported a slight miss on earnings per share (EPS) compared to analyst expectations. Despite the positive revenue news, the company’s stock faced a decline in the pre-market session. This reaction indicates investor concerns regarding the company’s future prospects. These developments come amid a competitive landscape in the biotech industry. The financial results have captured the attention of market analysts and investors alike. Adaptimmune’s earnings and revenue figures are crucial for stakeholders assessing the company’s performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.